Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters

被引:28
作者
Meurer, Rosalva Thereza
Martins, Daniele Tondolo
Hilbig, Arlete [1 ]
Ribeiro, Marlise de Castro
Roehe, Adriana Vial [2 ]
Barbosa-Coutinho, Ligia Maria
Fernandes, Marilda da Cruz [3 ]
机构
[1] Univ Fed Rio Grande do Sul, Med Clin, Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Dept Pathol, FAMED, Porto Alegre, RS, Brazil
[3] Univ Sao Paulo, Sao Paulo, Brazil
关键词
medulloblastoma; immunohistochemistry; Ki-67; NeuN; synaptophysin; HER2; p53; survival analysis;
D O I
10.1590/S0004-282X2008000300020
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Medulloblastoma (MB) is the most common malignant brain tumor in childhood. The alterations found include: presence of oncoproteins p53 and HER2, elevated mitotic index, and presence of neuronal differentiation. The aim of this study was to determine the immunohistochemical expression of markers Ki-67, NeuN, synaptophysin, HER2 and p53 in 40 MB samples and their correlation with clinicopathologic parameters and survival. In 29 patients (72.5%), >= 20% of cells were positive for Ki-67. Males showed greater ki-67 expression (p=0.02) and smaller survival rates (p=0.002). NeuN and synaptophysin were negative in 16 (40%) and 8 (20%) cases, respectively. P53 was positive in 18 (45%) cases, with 11 (61%) weakly positive and 7 (39%) strongly positive. HER2 was positive in 23 (57.5%) of the samples and did not show statistical association with survival (p=0.07).
引用
收藏
页码:385 / 390
页数:6
相关论文
共 27 条
  • [1] Review of the prognostic factors in medulloblastoma of children and adults
    Brandes, AA
    Paris, MK
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (02) : 121 - 128
  • [2] AN OPERATIVE STAGING SYSTEM AND A MEGAVOLTAGE RADIOTHERAPEUTIC TECHNIC FOR CEREBELLAR MEDULLOBLASTOMAS
    CHANG, CH
    HOUSEPIAN, EM
    HERBERT, C
    [J]. RADIOLOGY, 1969, 93 (06) : 1351 - +
  • [3] Classifying the medulloblastoma: insights from morphology and molecular genetics
    Ellison, D
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2002, 28 (04) : 257 - 282
  • [4] What's new in neuro-oncology? Recent advances in medulloblastoma
    Ellison, DW
    Clifford, SC
    Gajjar, A
    Gilbertson, RJ
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2003, 7 (02) : 53 - 66
  • [5] FERRARI AF, 2003, ARQ NEURO-PSIQUIAT, V61, pA3
  • [6] Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma
    Gajjar, A
    Hernan, R
    Kocak, M
    Fuller, C
    Lee, Y
    McKinnon, PJ
    Wallace, D
    Lau, C
    Chintagumpala, M
    Ashley, DM
    Kellie, SL
    Kun, L
    Gilbertson, RJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 984 - 993
  • [7] Clinical and molecular stratification of disease risk in medulloblastoma
    Gilbertson, R
    Wickramasinghe, C
    Hernan, R
    Balaji, V
    Hunt, D
    Jones-Wallace, D
    Crolla, J
    Perry, R
    Lunec, J
    Pearson, A
    Ellison, D
    [J]. BRITISH JOURNAL OF CANCER, 2001, 85 (05) : 705 - 712
  • [8] Medulloblastoma: signalling a change in treatment
    Gilbertson, RJ
    [J]. LANCET ONCOLOGY, 2004, 5 (04) : 209 - 218
  • [9] ERBB2 in pediatric cancer: Innocent until proven guilty
    Gilbertson, RJ
    [J]. ONCOLOGIST, 2005, 10 (07) : 508 - 517
  • [10] PROGNOSTIC-SIGNIFICANCE OF THE C-ERBB-2 ONCOGENE PRODUCT IN CHILDHOOD MEDULLOBLASTOMA
    GILBERTSON, RJ
    PEARSON, ADJ
    PERRY, RH
    JAROS, E
    KELLY, PJ
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (03) : 473 - 477